https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50452 Wed 26 Jul 2023 13:14:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41179 Wed 12 Jul 2023 11:51:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48060 Wed 06 Mar 2024 15:31:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36083 Wed 05 Feb 2020 13:13:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48579 Tue 21 Mar 2023 17:43:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43821 +ß7⁺ gut-homing T cells appear to be linked to the pathophysiology of both FD and IBS. Studies in the area are complicated by poor phenotyping of patients into subgroups and the subtle nature of the immune activity involved in FD and IBS. CONCLUSIONS: Alterations in proportions of gut-homing T lymphocytes in both FD and IBS indicate that a loss of mucosal homeostasis may drive the symptoms of FD and IBS. There is indirect evidence that Th17 responses may play a role in FGIDs, however the evidence for a Th2 immune phenotype in FD and IBS is limited. Although immune involvement is evident, large, well-characterised patient cohorts are required to elucidate the immune mechanisms driving the development of FGIDs.]]> Tue 04 Oct 2022 10:29:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45352 Thu 27 Oct 2022 11:46:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34597 Thu 13 Jan 2022 10:31:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47378 Thu 06 Jul 2023 13:38:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36099 Thu 06 Feb 2020 11:37:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36442 Mon 04 May 2020 14:01:05 AEST ]]>